Grimes & Company, Inc. Cassava Sciences Inc Transaction History

Grimes & Company, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 01, 2022	SELL	$36.77 - $90.91 $172,524 - $426,549	-4,692 Closed	0 $0
Q2 2021 Aug 04, 2021	BUY	$32.15 - $89.72 $150,847 - $420,966	4,692 New	4,692 $401,000

172

11.3M

1.61M

1.43M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $473M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Grimes & Company, Inc. with notifications on news.